Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of HC002 in Healthy Volunteers
NCT06670274Phase 1Completed
- Sponsor
- Holoclara
- Start
- Nov 2024
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HC002 in eosinophilic esophagitis (EoE) (3 arms), sponsored by Holoclara. Primary endpoints: Incidence of Adverse Events, Number of participants with abnormal laboratory values related to treatment and 1 more. Started Nov 2024; status: completed.
02
Drugs
HC002
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on NCT06670274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06670274.